UC2288,p21抑制剂
|
U276386-100mg
|
≥98% |
1394011-91-6 |
100mg
|
¥ 9999.9
|
现货 |
阿拉丁 |
松萝酸
|
U275043-200mg
|
≥98% |
125-46-2 |
200mg
|
¥ 29.9
|
现货 |
阿拉丁 |
松萝酸
|
U275043-1g
|
≥98% |
125-46-2 |
1g
|
¥ 57.9
|
现货 |
阿拉丁 |
URB597,FAAH抑制剂
|
U126873-500mg
|
Moligand™, ≥98% |
546141-08-6 |
500mg
|
¥ 671.9
|
期货,请咨询 |
阿拉丁 |
11-反-十八烯酸
|
T665791-500mg
|
≥97% |
693-72-1 |
500mg
|
¥ 3199.9
|
现货 |
阿拉丁 |
11-反-十八烯酸
|
T665791-100mg
|
≥97% |
693-72-1 |
100mg
|
¥ 999.9
|
现货 |
阿拉丁 |
1,1,4,4-四苯基-1,3-丁二烯
|
T485287-200mg
|
≥99%, suitable for scintillation |
1450-63-1 |
200mg
|
¥ 104.9
|
期货,请咨询 |
阿拉丁 |
3,5,5-三甲基己基丙烯酸酯
|
T476820-5ml
|
≥90%, 20-120 ppm MEHQ as inhibitor |
45125-03-9 |
5ml
|
¥ 369.9
|
现货 |
阿拉丁 |
3,5,5-三甲基己基丙烯酸酯
|
T476820-1ml
|
≥90%, 20-120 ppm MEHQ as inhibitor |
45125-03-9 |
1ml
|
¥ 99.9
|
现货 |
阿拉丁 |
TVB-3664
|
T414060-25mg
|
≥99% |
2097262-58-1 |
25mg
|
¥ 5999.9
|
现货 |
阿拉丁 |
TVB-3664
|
T414060-1mg
|
≥99% |
2097262-58-1 |
1mg
|
¥ 699.9
|
现货 |
阿拉丁 |
TVB-3664
|
T414060-10mg
|
≥99% |
2097262-58-1 |
10mg
|
¥ 2999.9
|
现货 |
阿拉丁 |
Tazemetostat (EPZ-6438)
|
T413712-250mg
|
Moligand™, ≥99% |
1403254-99-8 |
250mg
|
¥ 806.9
|
期货,请咨询 |
阿拉丁 |
Tazemetostat (EPZ-6438)
|
T413712-1g
|
Moligand™, ≥99% |
1403254-99-8 |
1g
|
¥ 3065.9
|
现货 |
阿拉丁 |
TD-165
|
T413699-50mg
|
≥96% |
2305936-56-3 |
50mg
|
¥ 1239.9
|
现货 |
阿拉丁 |
TD-165
|
T413699-10mg
|
≥96% |
2305936-56-3 |
10mg
|
¥ 599.9
|
现货 |
阿拉丁 |
TD-165
|
T413699-100mg
|
≥96% |
2305936-56-3 |
100mg
|
¥ 1999.9
|
现货 |
阿拉丁 |
Tirzepatide 钠盐
|
T412109-50mg
|
Moligand™, ≥99% |
2023788-19-2 |
50mg
|
¥ 3999.9
|
现货 |
阿拉丁 |
Tirzepatide 钠盐
|
T412109-25mg
|
Moligand™, ≥99% |
2023788-19-2 |
25mg
|
¥ 2499.9
|
现货 |
阿拉丁 |
Tirzepatide 钠盐
|
T412109-10mg
|
Moligand™, ≥99% |
2023788-19-2 |
10mg
|
¥ 1299.9
|
现货 |
阿拉丁 |
盐酸托屈嗪
|
T350965-5mg
|
≥98% |
3778-76-5 |
5mg
|
¥ 339.9
|
期货,请咨询 |
阿拉丁 |
盐酸托屈嗪
|
T350965-25mg
|
≥98% |
3778-76-5 |
25mg
|
¥ 859.9
|
期货,请咨询 |
阿拉丁 |
盐酸托屈嗪
|
T350965-1mg
|
≥98% |
3778-76-5 |
1mg
|
¥ 139.9
|
期货,请咨询 |
阿拉丁 |
盐酸托屈嗪
|
T350965-100mg
|
≥98% |
3778-76-5 |
100mg
|
¥ 1599.9
|
期货,请咨询 |
阿拉丁 |